1. Home
  2. LBRDK vs UTHR Comparison

LBRDK vs UTHR Comparison

Compare LBRDK & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LBRDK
  • UTHR
  • Stock Information
  • Founded
  • LBRDK 2014
  • UTHR 1996
  • Country
  • LBRDK United States
  • UTHR United States
  • Employees
  • LBRDK N/A
  • UTHR N/A
  • Industry
  • LBRDK Cable & Other Pay Television Services
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • LBRDK Telecommunications
  • UTHR Health Care
  • Exchange
  • LBRDK Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • LBRDK 8.4B
  • UTHR 20.7B
  • IPO Year
  • LBRDK N/A
  • UTHR 1999
  • Fundamental
  • Price
  • LBRDK $46.73
  • UTHR $470.12
  • Analyst Decision
  • LBRDK
  • UTHR Buy
  • Analyst Count
  • LBRDK 0
  • UTHR 12
  • Target Price
  • LBRDK N/A
  • UTHR $495.08
  • AVG Volume (30 Days)
  • LBRDK 1.1M
  • UTHR 568.9K
  • Earning Date
  • LBRDK 11-05-2025
  • UTHR 10-29-2025
  • Dividend Yield
  • LBRDK N/A
  • UTHR N/A
  • EPS Growth
  • LBRDK 1.38
  • UTHR 16.08
  • EPS
  • LBRDK 5.51
  • UTHR 26.38
  • Revenue
  • LBRDK $1,016,000,000.00
  • UTHR $3,128,400,000.00
  • Revenue This Year
  • LBRDK $8.37
  • UTHR $13.68
  • Revenue Next Year
  • LBRDK $2.91
  • UTHR $5.63
  • P/E Ratio
  • LBRDK $5.64
  • UTHR $17.68
  • Revenue Growth
  • LBRDK 306.40
  • UTHR 13.50
  • 52 Week Low
  • LBRDK $46.08
  • UTHR $266.98
  • 52 Week High
  • LBRDK $97.38
  • UTHR $479.50
  • Technical
  • Relative Strength Index (RSI)
  • LBRDK 24.64
  • UTHR 67.39
  • Support Level
  • LBRDK $49.61
  • UTHR $444.04
  • Resistance Level
  • LBRDK $49.77
  • UTHR $464.27
  • Average True Range (ATR)
  • LBRDK 2.20
  • UTHR 15.76
  • MACD
  • LBRDK -0.41
  • UTHR 1.66
  • Stochastic Oscillator
  • LBRDK 6.05
  • UTHR 84.40

About LBRDK Liberty Broadband Corporation Class C

Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: